Study reveals genetic link to cognitive decline in Parkinson’s disease

For decades, scientists believed that both the movement and memory problems of Parkinson’s disease stemmed from the same source: the toxic buildup of a protein called alpha-synuclein in the brain. But new research suggests that the two hallmarks of the disease — motor dysfunction and cognitive decline — actually arise from different biological mechanisms.

A study published in Nature Communications by a team at Yale School of Medicine shows that mutations in the GBA gene, a known risk factor for Parkinson’s, drive cognitive dysfunction by interfering with how brain cells communicate with one another.

“Dementia is often the scariest thing for many patients with Parkinson’s disease, more so than motor symptoms,” said Sreeganga Chandra, professor of neurology and neuroscience at Yale and the study’s senior author. “We are trying to understand the basis of cognitive dysfunction and whether we can find targets to ameliorate it.”

Separate causes for movement and memory symptoms

Using three different mouse models, researchers compared animals that carried excess alpha-synuclein, those with GBA mutations, and crossbred double mutants. The results were clear:

• Motor symptoms were linked to alpha-synuclein. Mice with excess protein developed worsening movement problems over time.
• Cognitive symptoms — including impaired memory and learning — appeared in mice with GBA mutations, whether or not alpha-synuclein was present.

By 12 months of age, GBA and double-mutant mice showed persistent cognitive deficits, while alpha-synuclein-only mice did not.

“This gives us confidence that we can use GBA mutations as a window to understand cognitive dysfunction in Parkinson’s disease,” said D.J. Vidyadhara, PhD, first author of the study.

Communication breakdown at the synapse

Digging deeper, the Yale team turned to single-cell RNA sequencing of brain tissue. They discovered that many genes related to synapses — the junctions where neurons send chemical messages to one another — were suppressed in GBA mutants.

Follow-up experiments confirmed actual loss of synapses in the cortex. That finding suggests that Parkinson’s dementia is not just about protein clumps clogging brain tissue, but about a more fundamental failure of neurons to communicate.

“GBA mutations cause cognitive deficits by modulating synaptic vesicle trafficking,” Chandra explained. In simple terms, the “packages” of neurotransmitters that neurons rely on to talk to one another get disrupted, leading to memory and concentration problems.

Implications for patients and treatments

The discovery opens new doors for Parkinson’s research. While alpha-synuclein aggregation remains a central focus for drug development, Chandra notes that not all patients show this pathology.

“There are aspects of the disease that are not driven at all by alpha-synuclein pathology, and we should be investigating these,” she said.

With as many as 80% of Parkinson’s patients eventually developing dementia, researchers hope that focusing on the GBA-synapse connection could yield new therapies that prevent or slow cognitive decline.